User:Mr. Ibrahem/Lanadelumab

Lanadelumab, sold under the trade name Takhzyro, is a medication used to prevent angioedema in people with hereditary angioedema. It is given by injection under the skin. It is used in people over the age of 12.

Common side effects include pain at the site of injection, upper respiratory infection, headache, rash, muscle pain, dizziness, and diarrhea. Other side effects may include allergic reactions. Safety in pregnancy is unclear. It is a monoclonal antibody that attaches to and blocks kallikrein (pKal).

Lanadelumab was approved for medical use in the United States and Europe in 2018. In the United States it costs about 685,000 USD per person per year when given every two weeks. In the United Kingdom this amount costs the NHS about £350,000.